SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): JUNE 14, 2001
-------------
IMS HEALTH INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 001-14049 06-1506026
------------- ----------------------------------- ----------------
(State of (Commission File Number) (IRS Employer
incorporation) Identification No.)
200 Nyala Farms
WESTPORT, CT 06880
-------------------------------------------- -------------
(Address of principal executive offices) (Zip Code)
(203) 222-4200
(Registrant's telephone number,
including area code)
_____________________________N/A____________________________
(Former name or former address, if changed since last report)
Items 1-8. Not Applicable.
Item 9. REGULATION FD DISCLOSURE.
------------------------
Representatives of management of IMS Health Incorporated (the "Company") made
an investor presentation at Goldman Sachs' 22nd Annual Healthcare Conference
on June 13, 2001. The Conference was well attended by members of the health
care investment community. For those who could not attend, presentation
slides are currently posted on the Company's website (WWW.IMSHEALTH.COM)
and will remain there for a period of time.
Subsequent to the Conference, on June 14, 2001, certain investors and securities
analysts requested additional information concerning the Company's disposition
in the first quarter of 2001 of IDRAC Holdings Inc. ("IDRAC") as previously
disclosed in the Company's Form 10-Q for the quarterly period ended March 31,
2001. The Company sold the stock of IDRAC to a wholly-owned subsidiary of
Information Holdings Inc. ("IHI") for aggregate potential consideration of
approximately US$ 10.5 million including an initial payment of US$ 5.5 million
and a contingent payment of US$ 5 million based on the future performance of
IDRAC. In a separate transaction, the Company also granted a nonexclusive
perpetual license to IHI to use certain data for aggregate cash consideration of
approximately US$ 17 million. Less than 50% of the $17 million in revenue
arising from the license transaction was recorded in the first quarter of 2001
pursuant to the revenue recognition requirements of US GAAP.
Had the foregoing transactions not been consummated in the first quarter of
2001, the Company's financial results would nonetheless have fallen within the
range of First Call consensus analyst performance expectations.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
IMS HEALTH INCORPORATED
By: /S/ JAMES C. MALONE
-------------------------------
Name: James C. Malone
Title: Chief Financial Officer
Date: June 15, 2001